Q1 Earnings Estimate for GPCR Issued By Leerink Partnrs

Structure Therapeutics Inc. (NASDAQ:GPCR) – Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for Structure Therapeutics in a research report issued to clients and investors on Monday, March 3rd. Leerink Partnrs analyst D. Risinger expects that the company will earn ($0.24) per share for the quarter. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.82) per share. Leerink Partnrs also issued estimates for Structure Therapeutics’ Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.29) EPS, FY2025 earnings at $1.80 EPS and FY2029 earnings at $1.03 EPS.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01.

Several other brokerages have also recently commented on GPCR. JMP Securities restated a “market outperform” rating and set a $91.00 target price on shares of Structure Therapeutics in a report on Wednesday, December 18th. Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price target for the company. William Blair assumed coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They issued an “outperform” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Structure Therapeutics in a research note on Thursday, December 19th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Trading Up 0.7 %

Shares of GPCR opened at $22.49 on Tuesday. Structure Therapeutics has a 12 month low of $19.61 and a 12 month high of $62.74. The firm has a fifty day simple moving average of $26.34 and a 200 day simple moving average of $33.37. The stock has a market capitalization of $1.29 billion, a price-to-earnings ratio of -30.39 and a beta of -2.75.

Institutional Trading of Structure Therapeutics

Hedge funds have recently modified their holdings of the stock. ANTIPODES PARTNERS Ltd lifted its stake in shares of Structure Therapeutics by 115.0% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock worth $28,000 after buying an additional 553 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Structure Therapeutics by 4,155.6% during the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after buying an additional 1,122 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Structure Therapeutics during the 4th quarter worth about $34,000. FNY Investment Advisers LLC acquired a new stake in shares of Structure Therapeutics during the 4th quarter worth about $40,000. Finally, Assetmark Inc. lifted its stake in shares of Structure Therapeutics by 120.0% during the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after buying an additional 719 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.